When looking for stocks to short, I tend to look for companies that fall into one of three categories:
The first category of stocks to short are stocks that are just wildly and insanely overvalued. However, often times, these stocks also tend to be momentum names like Netflix (NFLX), so you have to be careful when you initiate your short. The second category of stocks to short are those that are unquestionably going to go bankrupt at some point. JCPenney (JCP) is increasingly looking like one such example. The last category of stocks to short are those whose fundamentals and financials make the path of least resistance to be down.Here are four such candidates if you’re looking for stocks to short:
Top 5 Up And Coming Companies To Invest In 2015: Orbotech Ltd.(ORBK)
Orbotech Ltd. engages in designing, developing, manufacturing, marketing, and servicing yield-enhancing and production solutions for specialized applications in the supply chain of the electronics industry. The company?s products include automated optical inspection (AOI), automated optical repair, laser direct imaging, digital legend printing, laser drilling, laser plotters, computer-aided manufacturing, and engineering solutions for printed circuit boards (PCBs) and other electronics component manufacturing; and AOI, test, repair, and process monitoring systems for flat panel display (FPD) manufacturing. It also develops and markets character recognition solutions and services primarily to banks, financial institutions, and other payment processing institutions for use in check and healthcare payment processing. In addition, the company is involved in the research and development of products for the deposition of anti-reflective coating on crystalline silicon photovolta ic wafers for solar energy panels. It primarily serves manufacturer of PCB, FPD, liquid crystal displays, and other electronic components worldwide. The company was formerly known as Optrotech Ltd. and changed its name to Orbotech Ltd. as a result of its merger with Orbot Systems Ltd. in October 1992. Orbotech Ltd. was founded in 1981 and is headquartered in Yavne, Israel.
Advisors' Opinion:- [By John Emerson]
Orbotech (ORBK) and Rudolph Technologies (RTEC) Sizable Net-Nets in the AOI Sector
As noted previously, I rode the elevator up and then back down on Camtek (CAMT), a tiny Israeli automated optical inspection (AOI) company. By late 2008 the company had fallen to below $1 per share. Both of Camtek�� larger rivals, RTEC and ORBK, had dropped to absurdly low levels by November 2008. I used the opportunity to switch out of CAMT and some of my other losing propositions in favor of these superior companies. In the process, I created a large amount of tax loss carry-forwards which would allow me to minimize my future taxation when I decided to sell these cyclical entities.
- [By John Emerson]
AOI companies had little in the way of competition since they held a specialty niche and their systems were protected by patents. Years of R&D would be required to unseat them by way of technological superiority; therefore it made more sense for a larger company to assimilate them should they wish to enter the AOI sector. That said, CAMT was much smaller than its archrival Orbitech (ORBK) in the PCB AOI sector; thus their key to long term growth lied in their penetration into the rapidly expanding semiconductor AOI sector. In that area, their main completion was August Semiconductor.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Orbotech (Nasdaq: ORBK ) , whose recent revenue and earnings are plotted below.
Top Defensive Companies To Buy Right Now: Standard Pacific Corp(SPF)
Standard Pacific Corp. operates as a diversified builder of single-family attached and detached homes in the United States. It constructs homes targeting various homebuyers primarily move-up buyers in metropolitan markets in California, Florida, the Carolinas, Texas, Arizona, Colorado, and Nevada. The company also provides mortgage financing services to its homebuyers; and title examination services to its Texas homebuyers. As of December 31, 2011, it owned or controlled 26,444 homesites and had 166 active selling communities. Standard Pacific Corp. was founded in 1965 and is headquartered in Irvine, California.
Advisors' Opinion:- [By Sally Jones]
Standard Pacific Corp. (SPF): Reduced
Up 19% over 12 months, Standard Pacific Corp., a residential construction company, has a market cap of $2.27 billion. The current share price is around $8.18. Shares trade at a P/E of 5.70. The company does not pay a dividend.
- [By Louis Navellier]
If we look at those stocks trading with single-digit P/E ratios right now, it becomes a very simple task to separate the wheat from the chaff. There are many well-known stocks trading at low P/E ratios that get horrible grades from our system and should be avoided:
Ryland Homes (RYL) is a name you might hear discussed as a bargain, but the stock to a Sell back in November to a ����and is best avoided. Standard Pacific (SPF) is another builder you should probably avoid as In spite of the low P/E ratio ,you probably want to avoid discount retailer Big Lots (BIG), as a Strong Sell this week.But fear not — there are some great companies with solid fundamentals that earn a Buy ranking from Portfolio Grader and are better candidates for a low-P/E portfolio.
Top Defensive Companies To Buy Right Now: Invesco Plc(IVZ)
Invesco Ltd. is a publicly owned investment manager. The firm primarily provides its services to individuals, typically high net worth individuals. It also manages accounts for institutions. The firm manages separate client focused equity, fixed income, balanced portfolios. It also launches equity, fixed income, and balanced mutual funds for its clients. The firm invests in the public equity and fixed income markets across the globe. It invests in core, growth, and value stocks of small-cap, mid-cap, and large-cap companies. The firm employs a fundamental and quantitative analysis with a bottom-up stock picking approach to make its investments. It conducts in-house research to make its investments. Invesco Ltd. was founded in December 1935 and is based in Atlanta, Georgia.
Advisors' Opinion:- [By Dan Caplinger]
Lately, though, T. Rowe Price hasn't benefited as much from share-price gains. Competitor Invesco (NYSE: IVZ ) has managed to expand its margins and produce growth among its current lineup of funds, with exposure to a big range of markets that leaves it broadly placed to serve its customers' needs. But for T. Rowe Price and peer Federated Investors (NYSE: FII ) , investors haven't been putting as much money to work in their funds as analysts had expected to see, and that has led to some growth shortfalls. Federated in particular missed its earnings estimates in its most recent quarter, and analysts see growth there slowing to just 3%. T. Rowe Price has better prospects, retaining its double-digit revenue growth, but after a substantial move upward at the beginning of the year, its stock has treaded water.
- [By Ben Levisohn]
What a difference a day makes. After plunging yesterday, stocks gained today as investors came to terms with the Federal Reserve’s revised schedule for higher rates, sending shares of Invesco (IVZ), Zions Bancorporation (ZION), JPMorgan Chase (JPM) and Charles Schwab (SCHW) soaring.
- [By Sean Williams]
Investment management firm Invesco (NYSE: IVZ ) , which typically caters to high-net-worth individuals and offers a myriad of ETFs, rose 6.8% after reporting its first-quarter results. For the quarter, profits jumped nearly 15% to $0.49 per share as clients and investors flooded into its ETFs. Total cash inflows totaled $19.2 billion for the quarter -- a record for the company. It also didn't hurt that Invesco boosted its dividend by 30% to $0.225 per quarter. Even after today's move, at just 13 times forward earnings, there could still be room to run higher.
Top Defensive Companies To Buy Right Now: Vapor Corp (VPCO)
Vapor Corp (Vapor), incorporated in 1987, is engaged in designing, marketing and distributing electronic cigarettes and accessories under the Fifty-One, Krave, VaporX, EZ Smoker, Green Puffer, Americig, Fumre Hookah Stix and Smoke Star brands. Electronic cigarettes or e-cigarettes, are battery-powered products that enable users to inhale nicotine vapor without smoke, tar, ash, or carbon monoxide. Electronic cigarettes look like traditional cigarettes and consists of three functional components: a mouthpiece, which is a small plastic cartridge that contains a liquid nicotine solution; a heating element that vaporizes the liquid nicotine so that it can be inhaled; and the electronics, which include: a lithium-ion battery, an airflow sensor, a microchip controller and an light emitting diode (LED), which illuminates to indicate use. When a user draws air through the electronic cigarette, the air flow is detected by a sensor, which activates a heating element that vaporizes the solution stored in the mouthpiece/cartridge, the solution is then vaporized and it is this vapor that is inhaled by the user. The cartridge contains either a nicotine solution or a nicotine free solution, either of which may be flavored. The Company offers rechargeable and disposable electronic cigarettes in two varieties: a two-piece unit, which the Company markets under its DUO product line; and a three-piece unit, which the Company markets under its TRIO product line.
The DUO
The DUO's 2-part construction (battery component and cartridge) features a disposable all-in-one atomized cartridge (also known as a cartomizer). This cartomizer is replaced when the nicotine or nicotine free solution is depleted from use. The all-in-one configuration eliminates the need for maintenance of a separate atomizer and maintains consistent performance of the e-cigarette over time.
The TRIO
The TRIO's 3-part construction (battery component, atomizer, and filter cartridge) features a separate atom! izer from the cartridge; the atomizer is reused and requires separate maintenance over its useful life. Replacement atomizers are available for sale and are easily serviceable by the user. In the TRIO, the only component that needs to be routinely replaced is the refill cartridge (either with or without nicotine).
The Company's electronic cigarettes are sold in kits. In addition to kits the Company sells replacement batteries, replacement mouthpieces that contain the liquid solution and atomizer, for its two-piece configurations as well as mouthpieces with the liquid solution and separate atomizers for its three-piece units. In addition to the Company's electronic cigarette products the Company sells an assortment of accessories, including chargers and simple and fashionable cases. The Company also offers refill cartridges and accessories for its electronic cigarettes. The Company's refill cartridges consist of assorted flavors and nicotine levels (including cartridges without nicotine).
The Company competes with Altria Group, Inc. and Reynolds American Inc.,
Advisors' Opinion:- [By John Udovich]
While there is a�new ��tudy��out claiming�that�electronic cigarettes, or so-called e-cigarettes or e-cigs, may contain a comparable level of carcinogens to regular cigarettes,�speculative investors might still want to take a look at�small cap electronic cigarette stocks like�Hop-on, Inc (OTCMKTS: HPNN), Smokefree Innotec (OTCMKTS: SFIO), Vapor Corp (OTCMKTS: VPCO) and Victory Electronic Cigarettes Corp (OTCMKTS: ECIG) as these appear to be the major publicly traded small cap stocks left in the sector. I should note that�all of the�major big tobacco stocks have entered the electronic cigarette market (see Who Are the Big Tobacco Electronic Cigarette Stocks? MO, LO & RAI) through acquisitions or their own R&D initiatives, which might�mean�that an acquisition by big tobacco is off the table as an�exit strategy for investors. �Moreover and as I previously noted, there are concerns about the safety of electronic cigarettes as their popularity grows�while the Wall Street Journal recently reported that the FDA has been in discussions with the e-cigarette industry about a possible online-sales ban of the product.
- [By John Udovich]
Small cap electronic cigarette stocks Vapor Corp (OTCMKTS: VPCO), Smokefree Innotec�(OTCMKTS: SFIO), Hop-On Inc (OTCMKTS: HPNN) and American Heritage International Inc (OTCBB: AHII) are what�� left of the e-Cig market not controlled by ��ig Tobacco��and at least one of these stocks is positioning itself or its technology to exploit opportunities in marijuana or cannabis. Last year, industry experts were saying that�US retail sales of e-cigarettes could reach $1 billion for the year or�1% of the country's cigarette market but twice that of 2012�as sales go off the Internet and into more mainstream retailers. Moreover, they are being positioned as a ��ealthier��alternative to smoking (albeit some places have already extended their smoking bans to cover the devices). It should be stated that electronic cigarettes look just like traditional cigarettes and are usually comprised of three functional components:
- [By James E. Brumley]
Fans and investors of American Heritage International Inc. (OTCBB:AHII) - not to mention frenemies Vapor Corp. (OTCMKTS:VPCO) and Victory Electronic Cigarettes Corp. (OTCMKTS:ECIG) - can all breathe a sigh of relief today. As it turns out, while the electronic cigarette industry is more than likely be regulated by the FDA, it's going to be regulated in such a way that tends to favor the likes of AHII, ECIG, and VPCO.
Top Defensive Companies To Buy Right Now: AstraZeneca PLC (AZN)
AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�� products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. On August 31, 2011, the Company completed the sale of the Astra Tech business to DENTSPLY International Inc. On June 19, 2012, the Company acquired Ardea Biosciences Inc (Ardea), a biotechnology company in San Diego, California. In July 2012, the Company acquired a portfolio of neuroscience assets from Link Medicine Corporation. In August 2012, Alliance Pharma plc�� wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. In August 2012, the Company and Bristol-Myers Squibb Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company. In June 2013, the Company acquired Pearl Therapeutics.
Cardiovascular
The Company�� marketed products include Crestor (rosuvastatin calcium), Atacand2 (candesartan cilexetil), Seloken/Toprol-XL (metoprolol succinate), Tenormin (atenolol), Plendil (felodipine), Zestril3 (lisinopril dihydrate), Brilinta/Brilique (ticagrelor), and Axanum, (acetylsalicylic acid (ASA). Crestor1 is a statin used for the treatment of dyslipidaemia and hypercholesterolemia. In some markets, it is also indicated to slow the progression of atherosclerosis and to re! duce the risk of first cardiovascular (CV) events. Atacand2 is an angiotensin II antagonist used for the 1st line treatment of hypertension and symptomatic heart failure. Seloken/Toprol-XL is a beta-blocker once-daily tablet used for 24-hour control of hypertension and for use in heart failure and angina.
Tenormin is a cardioselective beta-blocker used for hypertension, angina pectoris and other CV disorders. Plendil is a calcium antagonist used for the treatment of hypertension and angina. Zestril3 is an angiotensin-converting enzyme inhibitor used for the treatment of a wide range of CV diseases, including hypertension. Brilinta/Brilique is an oral antiplatelet for the treatment of acute coronary syndromes (ACS). Axanum is a fixed dose combination indicated for prevention of CV events in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.
The Company�� marketed products for diabetes include Komboglyze ((saxagliptin and metformin HCl), Kombiglyze XR (saxagliptin and metformin XR) and Onglyza (saxagliptin). Komboglyze is an immediate release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets. Kombiglyze XR is an extended release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Onglyza is a DPP-IV inhibitor used for the treatment of Type 2 diabetes.
Gastrointestinal
AstraZeneca�� marketed products include Nexium (esomeprazole), Losec/Prilosec (omeprazole) and Entocort (budesonide). Nexium is a proton pump inhibitor (PPI) used for the treatment of acid-related diseases to offer clini! cal impro! vements over other PPIs and other treatments. Losec/Prilosec is used for the short-term and long-term treatment of acid-related diseases. Entocort is a corticosteroid used for the treatment of inflammatory bowel disease. Nexium is marketed in approximately 120 countries and is available in oral (tablet/capsules and oral suspension) and intravenous (i.v.) dosage forms for the treatment of acid-related diseases.
Infection
The Company�� marketed products include Merrem/Meronem (meropenem), Cubicin (daptomycin) and FluMist/Fluenz (influenza vaccine live, intranasal). Merrem/Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients. Cubicin is a cyclic lipopeptide anti-bacterial used for the treatment of serious infections in hospitalised patients. FluMist/Fluenz is an intranasal live, attenuated, trivalent influenza vaccine.
Neuroscience
AstraZeneca�� marketed products include Seroquel IR (quetiapine fumarate), Seroquel XR (an extended release formulation of quetiapine fumarate), Zomig (zolmitriptan), Diprivan (propofol), Vimovo (naproxen/esomeprazole magnesium), Naropin (ropivacaine), Xylocaine (lidocaine) and EMLA (lidocaine and prilocaine). Seroquel IR is an atypical anti-psychotic drug used for the treatment of schizophrenia and bipolar disorder (mania, depression and maintenance). Seroquel XR is used for the treatment of schizophrenia, bipolar disorder, MDD and in some territories for generalised anxiety disorder (GAD).
Zomig is used for the treatment of migraines with or without aura and Zomig Nasal Spray is indicated for the acute treatment of cluster. Diprivan is an intravenous general anaesthetic used in the induction and maintenance of general anaesthesia, for use in intensive care sedation and conscious sedation for surgical as well as diagnostic procedures. Vimovo is a fixed-dose combination of enteric-coated naproxen (an NSAID) with the gastroprotection of immediate release ! esomepraz! ole (a proton pump inhibitor) for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the developing of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Naropin is used as a long-acting local anaesthetic, for surgical anaesthesia and acute pain management. Xylocaine is a used short-acting local anaesthetic. EMLA is used as a local anaesthetic for topical application.
Oncology
AstraZeneca�� marketed products include Arimidex (anastrozole), Zoladex (goserelin acetate implant), Casodex (bicalutamide), Iressa (gefitinib), Faslodex (fulvestrant), Nolvadex (tamoxifen citrate) and Caprelsa (vandetanib). Arimidex is an aromatase inhibitor used for the treatment of early breast cancer. Zoladex, in one- and three-month depots, is a luteinising hormone-releasing hormone agonist used for the treatment of prostate cancer, breast cancer and certain benign gynaecological disorders. Casodex is an anti-androgen therapy used for the treatment of prostate cancer.
Advisors' Opinion:- [By Brian Orelli]
The class of diabetes drugs that Januvia belongs to, DPP-4 inhibitors, has increased immensely with the addition of AstraZeneca's (NYSE: AZN ) and Bristol-Myers Squibb's (NYSE: BMY ) Onglyza, which is approaching blockbuster status itself; sales were up 25% in the first quarter. And since Onglyza was approved, Eli Lilly�and Takeda have gained approval of DPP-4 inhibitors.
Top Defensive Companies To Buy Right Now: Paulson Capital Corp.(PLCC)
Paulson Capital Corp., through its subsidiary, Paulson Investment Company, Inc., operates as a brokerage company principally in the United States. It engages in securities brokerage activities, which include acting as agent for purchase and sale of common and preferred stocks, options, warrants, and debt securities traded on securities exchanges or in the over-the-counter market. The company?s corporate finance activities comprise underwriting initial and follow-on public offerings, private investments in public equity, and private placements for smaller companies; securities trading and market making activities consist of executing trades in equity securities, corporate debt securities, and municipal bonds; and market making activities are conducted with dealers in the wholesale market and its customers. Its investment activities include holding securities for investment, which primarily include securities purchased for investment and underwriter warrants. As of December 31, 2010, the company operated 39 branch offices in California, Colorado, Connecticut, Florida, Georgia, New Jersey, New York, Oregon, Utah, and Washington. Paulson Capital Corp. was founded in 1969 and is based in Portland, Oregon.
Advisors' Opinion:- [By CRWE]
Paulson Capital Corp. (Nasdaq:PLCC), parent company of Paulson Investment Company, Inc., reported a net income of $1,412,294 (or $0.24 per share) for the three months ended March 31, 2012 versus a net loss of $381,210 (or ($0.07) per share) for the like period in 2011.
No comments:
Post a Comment